(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 November 2006 (30.11.2006)

PCT

(10) International Publication Number
WO 2006/125622 A1

(51) International Patent Classification:
C07D 223/16 (2006.01) *A61P 25/18* (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:
PCT/EP2006/004954

(22) International Filing Date: 22 May 2006 (22.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0510599.4 24 May 2005 (24.05.2005) GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BRET, Celine** [FR/GB]; GlaxoSmithKline, Old Powder Mills, Near Leigh, Tonbridge Kent TN11 9AN (GB). **BURGESS, Sarah Jane** [GB/GB]; GlaxoSmithKline, Old Powder Mills, Near Leigh, Tonbridge Kent TN11 9AN (GB). **HOLLAS, Simon John** [GB/GB]; GlaxoSmithKline, Old Powder Mills, Near Leigh, Tonbridge Kent TN11 9AN (GB). **KING, Ian James** [GB/GB]; GlaxoSmithKline, Old Powder Mills, Near Leigh, Tonbridge Kent TN11 9AN (GB).

(74) Agent: **DOLTON, Peter, I.**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE

(57) **Abstract:** The present invention relates to a novel polymorphic form of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium maleate and a pharmaceutically acceptable solvate thereof, pharmaceutical formulation, process for its preparation and its use in medicine, in particular its use as an antipsychotic agent.

WO 2006/125622 A1